Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.93
-4.94 (-3.51%)
Streaming Delayed Price
Updated: 3:08 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
54
55
Next >
'Market's Had A Very Solid Winning Streak Of Late': Jim Cramer Eyes Key Retailers And CPI Data In Critical Earnings Week Ahead
November 11, 2023
CNBC market analyst Jim Cramer emphasized the importance of the upcoming week for investors,
Via
Benzinga
Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth
November 11, 2023
These stocks offer the best of both worlds.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
November 10, 2023
Via
Benzinga
3 Stocks to Buy for Retirees Looking to Beat Inflation
November 10, 2023
Retired investors looking to weather the current market with above-average returns should buy these inflation-beating retirement stocks.
Via
InvestorPlace
Topics
Retirement
Exposures
Pension
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years
November 02, 2023
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
November 10, 2023
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via
Benzinga
Widely Popular GLP-1-Based Weight Loss Drugs Reshape US Healthcare Landscape, May Help Control Addiction
November 10, 2023
Speakers at an event highlighted the impact of a new class of weight loss drugs, including substance abuse, on the U.S.
Via
Benzinga
'I Want You To Buy It, And Every Time It Dips, I Want You To Buy More': Cramer Hypes Up Auto Parts Retailer
November 10, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Broadcom Inc. (NASDAQ: AVGO) is a "buy."
Via
Benzinga
Could Novo Nordisk Stock Help You Retire a Millionaire?
November 10, 2023
The stock is up big this year, but it may surprise you just how massive your gains would need to be to reach $1 million.
Via
The Motley Fool
Novo Nordisk Seeks Obesity, Diabetes 'Bolt-On' Deals As It Beefs Up Capacity To Meet Soaring Demand
November 10, 2023
Novo Nordisk A/S (NYSE: NVO) plans to invest more than DKK 42 billion
Via
Benzinga
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
The major indexes ended long win streaks. Datadog led earnings winners.
Via
Investor's Business Daily
7 Biotech Stocks to Buy for Big-Time Gains
November 10, 2023
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research.
Via
InvestorPlace
The Stock-Split Stock Behind Ozempic and Wegovy Could Be Yours for Just $100
November 10, 2023
Novo Nordisk just reported financial and operating results through the first nine months of the year. One thing is clear: Demand is not an issue.
Via
The Motley Fool
Will Eli Lilly's Zepbound be the next big weight-loss drug?
November 10, 2023
Eli Lilly got regulators' OK for weight-loss drug Zepbound, which will compete with Novo Nordisk's Wegovy. Analysts see Zepbound sales as high as $37 billion
Via
MarketBeat
Look Out, Ozempic and Wegovy: Eli Lilly Has a New Weight-Loss Drug in Town
November 10, 2023
Analysts predict Lilly's tirzepatide, marketed under the Mounjaro and Zepbound brands, could achieve peak annual sales of more than $50 billion.
Via
The Motley Fool
Lilly's Strategic Branding Move For Weight Loss Drug Sets Stage For Long Term Success - Analyst
November 09, 2023
Wednesday, the FDA approved Eli Lilly And Co's (NYSE: LLY) Zepbound (tirzepatide) injection, the first and
Via
Benzinga
Exposures
Product Safety
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
November 09, 2023
The company is licensing a new GLP-1 drug in the hopes of taking on Novo and Lilly.
Via
Investor's Business Daily
Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?
November 09, 2023
This competition is leading to a lot of serious innovation.
Via
The Motley Fool
Novo Nordisk Ceases Production Of One Long-Acting Insulin In US Amid Manufacturing Constraints, Competition
November 09, 2023
Novo Nordisk A/S (NYSE: NVO) has reportedly discontinued its long-acting insulin Levemir in the U.S., attributing the decision to manufacturing constraints, reduced patient access, and the availability...
Via
Benzinga
People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk Billions
November 09, 2023
Medicines can sell more when patients understand that they're priced accessibly.
Via
The Motley Fool
Weight Loss Drug Competition - FDA Approves Expanded Use Of Eli Lilly's Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk's Price
November 08, 2023
The FDA has approved
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
November 08, 2023
Via
Benzinga
Why Novo Nordisk Stock Trounced the Market Today
November 06, 2023
A pair of pundits became notably more bullish on the company in the wake of its latest results announcement.
Via
The Motley Fool
European Pharma Rules Overhaul, Concerns Arise Over Billions In Lost Investment, Undiscovered Treatments
November 06, 2023
The European Federation of Pharmaceutical Industries and Associations (EFPIA)
Via
Benzinga
Why Novo Nordisk Stock Flopped on Friday
November 03, 2023
The news items about the company Friday were two molehills that no investor should make into mountains.
Via
The Motley Fool
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
November 03, 2023
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and...
Via
Benzinga
Topics
Bonds
Economy
Exposures
Debt Markets
Interest Rates
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
November 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
November 03, 2023
Bulls are back in control as the major indexes confirmed the uptrend this week.
Via
Investor's Business Daily
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
November 03, 2023
Lilly's Mounjaro is gaining ground on Novo Nordisk's Ozempic.
Via
The Motley Fool
1 Stock-Split Stock to Buy Hand Over Fist in November, and 1 to Avoid
November 03, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a phenomenally cheap industry leader, as well as an exceptionally pricey company...
Via
The Motley Fool
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.